Literature DB >> 20875623

Minimally traumatic midface lift approach for patients in their early 30s and 40s.

Xiao-Gen Hu1, Hai-Huan Ma, Xiao-Zu Fu, Gao Zeng, Hui Lu, Peng Cui, Hui-Jie Qi.   

Abstract

BACKGROUND: To evaluate the effectiveness of the minimally traumatic midface lift approach in combination with the Wrinkle Severity Rating Scale (WSRS) criteria.
METHODS: From July 2007 to September 2009, 21 female patients underwent the minimal incision midface lift procedure. The procedure was mainly composed of a small arrow-like incision just superior to the top of the auricle, a fanlike subcutaneous dissection, and 3 suspension sutures. After 6 months, objective and subjective criteria were recorded, photos were taken for documentation and the WSRS scale system was used. Postoperative adverse effects were also recorded.
RESULTS: All 21 patients completed more than a 6-month postoperative follow-up, and all the patients gained complete recovery. In the doctor's evaluation for using the WSRS system, 3 patients (14.3%) felt fair, the remaining 18 patients (85.7%) felt good, and no patients (0%) had poor results 6 months after the operation. In patient self-evaluation, 5 patients (23.8%) felt fair, the remaining 16 (76.2%) felt good, and no patient (0%) had poor results after 6 months. No serious operative complications including facial nerve palsy and skin slough were found.
CONCLUSION: The minimally traumatic midface lift is a simple, reliable, and effective approach for the aging face of women in their 30s and 40s.
Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20875623     DOI: 10.1016/S1726-4901(10)70104-0

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  1 in total

1.  Endoscopic facelift of the frontal and temporal areas in multiple planes.

Authors:  Xiaogen Hu; Haihuan Ma; Zhiqiang Xue; Huijie Qi; Bo Chen
Journal:  Singapore Med J       Date:  2016-02-19       Impact factor: 1.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.